Could Albuminuria Be an Overlooked Marker of Thrombotic Risk? – RPTH Journal
RPTH Journal shared a post on LinkedIn about a recent article by Xiu Hong Yang et al, adding:
”Could albuminuria be an overlooked marker of thrombotic risk?
We usually think of the urine albumin-to-creatinine ratio (UACR) as a kidney or cardiovascular marker.
But what if it also reflects systemic thrombotic vulnerability?
A new prospective RPTH study of 419,282 UK Biobank participants examined the relationship between albuminuria and future arterial thromboembolism (ATE) and pulmonary embolism (PE).
Here’s the key signal:
- Moderate albuminuria (UACR 3–30 mg/mmol) increased ATE risk
- Severe albuminuria (>30 mg/mmol) increased the risk of both ATE and c
- Risk intensified further with reduced kidney function or low serum albumin
What’s changing under the hood:
- Albuminuria reflects endothelial dysfunction and vascular injury
- Associated with platelet activation and hypercoagulability
- Linked to inflammatory pathways (CRP, VWF, ADAMTS13)
- Suggests a systemic prothrombotic state – not just kidney disease
(Figures 1–3 show dose-dependent increases in thrombotic risk with rising UACR)
Translation:
Albuminuria may not simply mark renal injury; it may identify patients with heightened endothelial and thrombotic dysfunction.
Big questions for the field:
- Should UACR be incorporated into thrombosis risk assessment?
- Is albuminuria a mediator of thrombosis – or a marker of systemic vascular injury?
- Could aggressive treatment of albuminuria reduce thromboembolic events?”
Title: Urine albumin-to-creatinine ratio and risks of incident arterial thromboembolism and pulmonary embolism among adults—a prospective cohort study
Authors: Xiu Hong Yang, Yao Liu, Zhen Xing Zhang, Yi Jun Lu, Chen Sheng Fu, Hui Min Jin, Zhi Bin Ye, Xiao Li Zhang

Stay updated on all scientific advances with Hemostasis Today.
-
Sep 24, 2026, 12:56Maria Helena Parrinello: A New Score for Chronic GvHD Risk Assessment at the SIE Congress
-
Sep 24, 2026, 12:44Shehab Mohamed: TP53 Mutations and Outcomes in Myeloproliferative Neoplasms
-
Sep 24, 2026, 12:34Francesca Palandri: Is There Still a Place for Splenectomy in ITP in the Modern Era?
-
Sep 24, 2026, 12:15Cedric Hermans: RPTH Illustrated Review on Von Willebrand Disease
-
Sep 24, 2026, 11:48Factor XII Inhibition and the Future of Contact Pathway Targeting
-
Sep 24, 2026, 08:55Andres Gudino: Clot Characterization Through Hounsfield Units in Ischemic Stroke
-
Sep 24, 2026, 06:52Gina Sado: Screening-Detected Atrial Fibrillation Carries High Risk of Heart Failure
-
Sep 24, 2026, 06:33Benjamin Vipler: Optimal Oral Anticoagulation Choice in Atrial Fibrillation and Advanced CKD
-
Sep 24, 2026, 06:08Christopher Salerno: AI-Powered At-Home Anemia Screening Advances Telehealth Access